Evidence map›Paper›PMID 39714988›Full record

ArticleChemMedChem2025

Elucidating the High Affinity Copper(II) Complexation by the Iron Chelator Deferasirox Provides Therapeutic and Toxicity Insight.

Aixa M Orta Rivera, Luis A Landrau Correa, Selene L Schiavone-Chamorro, Moriana Rankins, Mariela V Pérez Otero, Josué A Benjamín-Rivera, José A Vega Aponte, Valerie B Ebenki, Adriana I Vargas Figueroa, Andrei V Astashkin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aixa M Orta RiveraDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Luis A Landrau CorreaDepartment of Biology, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Selene L Schiavone-ChamorroDepartment of Biology, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Moriana RankinsDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Mariela V Pérez OteroDepartment of Biology, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Josué A Benjamín-RiveraDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
José A Vega AponteDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Valerie B EbenkiDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Adriana I Vargas FigueroaDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.
Andrei V AstashkinDepartment of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ, 85721-0041, United States.
Lauren Fernández-VegaDivision of Science, Technology, and Environment, University Ana G. Méndez-Cupey Campus, 1399 Av. Ana G. Méndez, San Juan, PR, 00926, United States.
Arthur D TinocoDepartment of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico, 00925-2537, United States.ORCID https://orcid.org/0000-0003-2825-5235

Funding

Upgrade Laboratories Facilities at UPR-Rio PiedrasR25GM061151 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2001 to 2023
$32.5M
Research Projects CoreP30GM149367 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Walter I Silva · 2023 to 2026
$5.6M
Development of Peptide-Conjugate Biomimics for Targeted Ti(IV)-Based Anticancer DSC1CA190504 · NCI · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI TINOCO, ARTHUR DAVID · 2014 to 2017
$1.4M
Fusing the commercial drugs triapine and deferasirox to create Ti(IV) anticancer compounds that inhibit the bioavailability of ironR21CA240997 · NCI · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI TINOCO, ARTHUR DAVID · 2020 to 2020
$370k
G-RISE at the University of Puerto Rico Rio PiedrasT32GM152384 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2024 to 2024
$329k
URISE at the University of Puerto Rico Rio PiedrasT34GM153667 · NIGMS · UNIVERSITY OF PUERTO RICO RIO PIEDRAS · PI CARBALLEIRA, NESTOR MANUEL · 2024 to 2024
$130k
American Cancer Discovery Boost DBG-23-1156894-01-ETCenter for Neuroplasticity at the University of Puerto Rico COBRE II 1T34 GM153667-01Center for Neuroplasticity at the University of Puerto Rico COBRE II 5P30 GM149367MSEIP P120 A210035NCI NIH HHS R21 CA240997NCI NIH HHS SC1 CA190504NIGMS NIH HHS P30 GM149367NIGMS NIH HHS R25 GM061151NIGMS NIH HHS T32 GM152384NIGMS NIH HHS T34 GM153667NIH HHS 1R21CA240997-01 A1NIH HHS 5SC1CA190504NSF REU 1757365NSF REU 2349168NSF STC Bioxfel 1231306Proyecto Título V 1T32 GM152384-01Proyecto Título V 5R25 GM061151Proyecto Título V PO31S200104
6 · The paper itself

Abstract

Tinoco A-Team Deferasirox (Def), an orally administered iron-chelating drug, has drawn significant interest in repurposing for anticancer application due to the elevated Fe demand by cancer cells. But there are also concerns about its severe off target health effects. Herein Cu(II) binding is studied as a potential off target interaction. The aqueous solution stability and speciation of the ternary complex Cu(Def)(pyridine) was studied by UV-Vis and EPR spectroscopy, ESI-mass spectrometry, and cyclic voltammetry under physiologically relevant conditions. The complex is observed to be a redox active, mononuclear Cu(II) complex in square planar geometry. UV-Vis spectroscopy demonstrates that at pH 7.4 the complex is quite stable (ϵ

Indexed as

Antineoplastic AgentsBenzoatesCoordination ComplexesCopperDeferasiroxIron Chelating AgentsTriazolesAnimalsCattleCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureAntineoplastic AgentsBenzoatesCoordination ComplexesCopperDeferasiroxIron Chelating AgentsTriazolesCancerCopperDeferasiroxIron chelatorToxicity

Identifiers

PMID39714988
PMCPMC13528216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.